Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study

被引：39
|
作者：
Cunha, Mirella A. [1 ]
Leao, Aline C. Q. [1 ]
Soler, Rita de Cassia [1 ]
Lindoso, Jose Angelo L. [1 ,2 ]
机构：
[1] Inst Infectol Emilio Ribas, Sao Paulo, Brazil
[2] Univ Sao Paulo, Inst Trop Med, Lab Soroepidemiol LIM HC FMUSP 38, Sao Paulo, Brazil
来源：
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE | 2015年 / 93卷 / 06期
基金：
巴西圣保罗研究基金会;
关键词：
MUCOCUTANEOUS LEISHMANIASIS; CUTANEOUS LEISHMANIASIS; DIAGNOSIS; TOXICITY; PCR;
D O I：
10.4269/ajtmh.15-0033
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
The standard treatment of mucosal leishmaniasis (ML) is pentavalent antimonials, agents with serious adverse effects. Alternative agents include amphotericin B deoxycholate and liposomal amphotericin B. We performed a retrospective study including 29 patients treated with liposomal amphotericin B, most of whom had comorbidities, history of previous treatment of ML, and contraindications to the use of antimonial pentavalent or amphotericin B deoxycholate. We observed a cure rate of 93.1%. Kidney failure was the most important side effect, reported in five patients (17.2%). This study showed a good efficacy and safety profile of liposomal amphotericin B in patients with ML and contraindications to the use of other agents.
引用
收藏
页码：1214 / 1218
页数：5
相关论文
共 50 条
  • [31] Rapidly progressing facial leishmaniasis: effective treatment with liposomal amphotericin B and a review of the management of Old World cutaneous leishmaniasis
    Islam, Shamim
    [J]. PAEDIATRICS AND INTERNATIONAL CHILD HEALTH, 2018, 38 (02) : 158 - 161
  • [32] Successful response to liposomal amphotericin B in mucosal leishmaniasis in glans resistant to intralesional pentavalent
    Aguayo-Carreras, Paula
    Cuenca-Barrales, Carlos
    Perez-Lopez, Israel
    Ruiz-Villaverde, Ricardo
    Tercedor-Sanchez, Jesus
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2019, 58 (07) : E137 - E138
  • [33] Pilot study of safety and efficacy of topical liposomal amphotericin B for cutaneous leishmaniasis caused by Leishmania major in Islamic Republic of Iran
    Khamesipour, Ali
    Mohammadi, Akram
    Jaafari, Mahmoud
    Eskandari, Seyed
    Tasbihi, Minoo
    Javadi, Amir
    Afshari, Farzaneh
    Mortazavi, Hossein
    Firooz, Alireza
    [J]. EASTERN MEDITERRANEAN HEALTH JOURNAL, 2022, 28 (09) : 658 - 663
  • [34] Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study
    Mondal, Dinesh
    Alvar, Jorge
    Hasnain, Md Golam
    Hossain, Md Shakhawat
    Ghosh, Debashis
    Huda, M. Mamun
    Nabi, Shah Golam
    Sundar, Shyam
    Matlashewski, Greg
    Arana, Byron
    [J]. LANCET GLOBAL HEALTH, 2014, 2 (01): : E51 - E57
  • [35] Short Report: Can We Use a Lower Dose of Liposomal Amphotericin B for the Treatment of Mucosal American Leishmaniasis?
    Amato, Valdir S.
    Tuon, Felipe F.
    Camargo, Raphael A.
    Souza, Regina M.
    Santos, Carolina R.
    Nicodemo, Antonio C.
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2011, 85 (05): : 818 - 819
  • [36] Treatment of mucosal leishmaniasis with amphotericin B lipid complex (ABLC)
    Tuon, Felipe Francisco
    Santos, Carolina Rocio
    Cieslinski, Juliette
    de Souza, Regina Maia
    Imamura, Rui
    Amato, Valdir Sabbaga
    [J]. REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, 2018, 60
  • [37] Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B
    Groll, Andreas H.
    Rijnders, Bart J. A.
    Walsh, Thomas J.
    Adler-Moore, Jill
    Lewis, Russell E.
    Bruggemann, Roger J. M.
    [J]. CLINICAL INFECTIOUS DISEASES, 2019, 68 : S260 - S274
  • [38] A Case of Cutaneous Leishmaniasis Responding to Systemic Liposomal Amphotericin B Treatment
    Taskin, Esra Cakmak
    Kutukcu, Hatice Busra
    Konca, Hatice Kubra
    Arga, Gul
    Ozdemir, Halil
    Akay, Bengu Nisa
    Ciftci, Ergin
    Ince, Erdal
    [J]. JOURNAL OF PEDIATRIC INFECTION, 2020, 14 (04): : 247 - 250
  • [39] Treatment of visceral leishmaniasis with liposomal amphotericin B in three immunocompromised patients
    Rodríguez-Wilhelmi, P
    Panizo, C
    Ruza, E
    Rocha, E
    [J]. MEDICINA CLINICA, 2001, 116 (01): : 37 - 38
  • [40] Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis
    Brown, M
    Noursadeghi, M
    Boyle, J
    Davidson, RN
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (01) : 203 - 205
12345